Literature DB >> 16940769

Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms.

Puneet Kumar1, Satyanaryana Sreenivasulu Venketswera Padi, Pattipati Sreenivasulu Naidu, Anil Kumar.   

Abstract

Huntington's disease is a progressive, degenerative disease characterized by abnormal body movements called chorea, and a reduction of various mental abilities. 3-Nitropropionic acid, an inhibitor of complex II of the electron transport chain, causes Huntington's disease-like symptoms in rodents. Recently, it has been reported that oxidative stress, which is one of the pathological hallmarks of various neurodegenerative disorders, also plays an important role in the pathogenesis of Huntington's disease. The present study was designed to investigate effects of resveratrol, an antioxidant with cyclooxygenase I inhibitory activity, in the 3-nitropropionic acid-induced model of Huntington's disease. Intraperitoneal administration of 3-nitropropionic acid (20 mg/kg for 4 days) caused significant loss of body weight, a decline in motor function (locomotor activity, movement pattern and vacuous chewing movements) and poor retention of memory. Repeated treatment with resveratrol (5 and 10 mg/kg, orally), once daily for a period of 8 days beginning 4 days prior to 3-nitropropionic acid administration, significantly improved the 3-nitropropionic acid-induced motor and cognitive impairment. Biochemical analysis revealed that systemic 3-nitropropionic acid administration significantly increased lipid peroxidation, nitrite levels, and depleted reduced glutathione levels, and decreased succinate dehydrogenase activity in the brains of rats. The results of the present study indicate that resveratrol (5 and 10 mg/kg, orally) significantly reversed 3-nitropropionic acid-induced motor and cognitive impairment, and that the beneficial effects of resveratrol might be attributed to its antioxidant activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940769     DOI: 10.1097/00008877-200609000-00014

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  49 in total

Review 1.  Energy deficit in Huntington disease: why it matters.

Authors:  Fanny Mochel; Ronald G Haller
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

2.  Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington's disease.

Authors:  Yan Gao; Shi-feng Chu; Jian-ping Li; Zhao Zhang; Jia-qing Yan; Zhi-lin Wen; Cong-yuan Xia; Zheng Mou; Zhen-zhen Wang; Wen-bin He; Xiao-feng Guo; Gui-ning Wei; Nai-hong Chen
Journal:  Acta Pharmacol Sin       Date:  2015-02-02       Impact factor: 6.150

3.  Targeting sirtuin-1 in Huntington's disease: rationale and current status.

Authors:  Wenzhen Duan
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

4.  Organoselenium bis selenide attenuates 3-nitropropionic acid-induced neurotoxicity in rats.

Authors:  Cristiani F Bortolatto; Cristiano R Jesse; Ethel A Wilhelm; Pietro M Chagas; Cristina W Nogueira
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 5.  SIRT1 in neurodevelopment and brain senescence.

Authors:  A Zara Herskovits; Leonard Guarente
Journal:  Neuron       Date:  2014-02-05       Impact factor: 17.173

Review 6.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

7.  Effects of resveratrol on alterations in cerebrum energy metabolism caused by metabolites accumulated in type I citrullinemia in rats.

Authors:  Karine Louize Vincenzi; Thayna Patachini Maia; Larissa Delmônego; Aline Barbosa Lima; Luana Carla Pscheidt; Débora Delwing-Dal Magro; Daniela Delwing-de Lima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-11-18       Impact factor: 3.000

Review 8.  Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Authors:  Joao Tomé-Carneiro; Mar Larrosa; Antonio González-Sarrías; Francisco A Tomás-Barberán; María Teresa García-Conesa; Juan Carlos Espín
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 9.  Epigenetic regulation of astrocyte function in neuroinflammation and neurodegeneration.

Authors:  Matthew Neal; Jason R Richardson
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-11-04       Impact factor: 5.187

10.  Protective effects of epigallocatechin gallate following 3-nitropropionic acid-induced brain damage: possible nitric oxide mechanisms.

Authors:  Puneet Kumar; Anil Kumar
Journal:  Psychopharmacology (Berl)       Date:  2009-09-18       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.